EUCTR2010-020693-42-SK进行中（未招募）不适用
A randomised, double-blind, placebo-controlled, multi-national, Phase IIIb study to assess the sustained clinical effect and safety of sublingual immunotherapy administered as birch pollen extract solution at a dose of 300 I.R. once daily to patients suffering from birch pollen-induced rhinoconjunctivitis - V068.10
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 544
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •The main inclusion criteria are:
- •- Male or female outpatients aged 18 to 65 years (inclusive).
- •- Symptomatic birch pollen-related allergic rhinoconjunctivitis for at least the previous 2 pollen seasons requiring intake of symptomatic treatment.
- •- Sensitization to birch pollen demonstrated by:
- •A positive SPT to birch pollen with wheal diameter > 3 mm.
- •Birch pollen allergens specific IgE levels = 0.70 kU/L.
- •- RRTSS based on the previous or on the penultimate birch pollen season = 12 out of a maximum possible score of 18.
- •- Patients with an FEV1 = 80% of the predicted value.
- •- Patients who are willing to comply with the protocol.
- •- Patients having given a signed informed consent before completing any study related procedure.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Exclusion Criteria:
- •-Patients with symptoms of rhinitis/rhinoconjunctivitis during the birch pollen season due to any other allergens (except alder and hazel). This includes patients with symptomatic allergic rhinitis/rhinoconjunctivitis due to cat or dog allergens, and living with these animals at home or at risk of frequent contacts with these animals (family, friends etc.) during the course of the study.
- •-Patient who previously received desensitization treatment to birch pollen and/or another Betulaceae sp. (for example hazel or alder) within the previous 5 years.
- •-Patients with ongoing treatment by immunotherapy with another allergen.
- •-Pregnancy (positive pregnancy test), breast-feeding.
- •-Female patients of childbearing potential planning a pregnancy during this study or not using a medically accepted contraceptive method (hormonal birth control [orally, injectable or by implant, for at least 2 months before enrolment], intrauterine device, spermicide used with a male condom, bilateral tubal ligation, diaphragm with spermicide, female condom, monogamous relationship with a vasectomised partner).
- •- Patients planning to move during the study or planning to leave the area during the birch pollen season for more than 1 week (7 consecutive days).
- •- Patients with moderate or severe persistent asthma (GINA 3 or 4).
- •- Patients with seasonal mild persistent asthma (GINA 2) necessitating treatment with inhaled glucocorticosteroids at a dose level greater than 400 mcg budesonide dose-equivalents.
- •- Patients with any nasal or oral condition that could interfere with the efficacy or safety assessments (such as nasal polyposis or oral inflammation).
- •- Patients with severe immune deficiency.
- •- Patients with a past or current disease, which as judged by the Investigator, may affect the patient’s participation in or outcome of this study.
- •- Any other disease or condition which would place a patient at undue risk by being included in the study (according to the Investigator’s opinion).
- •- Usual contra-indications of immunotherapy such as concomitant beta-blocker therapy whatever the route and/or immunosuppressive drugs.
- •- Patients treated with inhaled/systemic steroids (whatever the indication) within 4 weeks prior to Visit 1 (Screening), or with long acting systemic corticosteroids 12 weeks before Visit 1 (Screening).
- •- Patients under continuous corticotherapy (inhaled or systemic drugs).
- •- Patients following a strict low sodium diet as the study treatment contains 590 mg of sodium chloride per vial in a 10 mL solution.
- •- Investigators, co-Investigators, as well as their children or spouses and all study collaborators.
- •- Patients who have participated in any clinical trial within 3 months prior to this one.
研究者
相似试验
进行中（未招募）
1 期
A randomised, double-blind, placebo-controlled, multi national, Phase III study of the efficacy and safety of 300 IR sublingual immunotherapy (SLIT), starting 2 months before the grass pollen season, administered as allergen based tablets once daily to patients suffering from grass pollen rhinoconjunctivitis (with or without asthma)Grass pollen allergic rhinoconjunctivitisMedDRA version: 9.1Level: LLTClassification code 10039085Term: Rhinitis allergicMedDRA version: 9.1Level: PTClassification code 10039085Term: Rhinitis allergicEUCTR2008-003906-32-CZStallergenes S.A.336
进行中（未招募）
不适用
A randomised, double-blind, placebo-controlled, multicentre, Phase II dose-finding study of atacicept given subcutaneously in subjects with rheumatoid arthritis and inadequate response to TNFa antagonist therapy - A Phase II dose-finding study of atacicept in RAMedDRA version: 8.1Level: LLTClassification code 10039073Term: Rheumatoid arthritisRheumatoid arthritisEUCTR2006-004140-23-PTMerck Serono Int, a branch of Laboratoires Serono SA an affiliate of Merck KGaA, Darmstadt, Germany240
进行中（未招募）
1 期
A clinical study to assess the long-term efficacy and safety of lanifibranor followed by an active treatment extension in adult patients with non-cirrhotic non-alcoholic steatohepatitis (NASH) and fibrosis 2 (F2)/fibrosis 3 (F3) stage of liver fibrosison-alcoholic Steatohepatitis (NASH)MedDRA version: 24.1Level: PTClassification code 10053219Term: Non-alcoholic steatohepatitisSystem Organ Class: 10019805 - Hepatobiliary disordersEUCTR2020-004986-38-HUInventiva S.A.1,200
进行中（未招募）
不适用
A randomised, double-blind, placebo-controlled, multicentre trial to access the safety and efficacy of pre-treatment with DF01 during late pregnancy in reducing prolonged labour.Pre-treatment during late pregnancy to reduce prolonged labour.EUCTR2006-005839-20-SEDilafor AB
进行中（未招募）
不适用
A single-dose study to investigate the effects of 3 different doses of inhaled AZD2115 in COPD patientsAZD2115 is being developed to treat chronic obstructive pulmonary disease (COPD).MedDRA version: 14.1Level: LLTClassification code 10010952Term: COPDSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2011-004641-41-PLAstraZeneca AB36